3019462
print

Anti-Mutated Citrullinated Vimentin (MCV) Antibody, Serum

ANTI-MCVAB

Ordering Recommendation

Use only as an aid in the diagnosis of rheumatoid arthritis in conjunction with other laboratory and clinical findings.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube (SST).

Specimen Preparation

Separate serum from cells as soon as possible or within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.5 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Contaminated, heat-inactivated, grossly hemolyzed, grossly icteric, or grossly lipemic specimens.

Remarks
Stability

Ambient: 48 hour; Refrigerated: 5 days; Frozen: 30 days; samples should be frozen and thawed only once. Samples that are improperly stored or are subject to multiple freeze-thaw cycles may yield spurious results.

Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)

Performed

Wed

Reported

1-8 days

Reference Interval

Less than or equal to 19.9 U/mL

Interpretive Data

Anti-MCV antibody concentrations of ≥20 U/mL is used as a positivity cutoff according to the assay's package insert and an internal verification study. Positive results should be interpreted in the context of patient's clinical presentation, laboratory and/or radiologic findings, and current disease guidelines.

Anti-MCV can be found in patients negative for anti-CCP antibodies. Anti-MCV can be a useful marker for early RA diagnosis, and positivity has been associated with disease activity and poor radiographic prognosis.

Compliance Category

FDA

Note

Vimentin is an intermediate filament protein secreted by macrophages in inflamed joints. Mutated citrullinated vimentin (MCV) is a modified protein found in the synovial fluids of subjects with rheumatoid arthritis (RA). MCV can induce the formation of autoantibodies (anti-MCV). Anti-MCV antibodies can be of higher sensitivity in the diagnosis of RA and can be found in patients negative for anti-CCP. Anti-MCV can be a useful marker for early RA diagnosis, and positivity has been associated with disease activity and poor radiographic prognosis.

This assay uses ELISA methodology for the detection of anti-MCV antibodies. MCV is bound to microwells. If antibodies to MCV are present in the tested patient sample, they will bind to the antigens on the microwells. Enzyme conjugated anti-human secondary antibodies are then added, followed by the addition of a substrate to generate a color reaction. The intensity of the color is proportional to the bound anti-MCV IgG antibodies and is measured using a spectrophotometer.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
04/21/2025
X
N/A

CPT Codes

83520

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
3019463 Anti-MCV IgG Antibody 54022-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • RA
  • Mutated citrullinated vimentin antibodies
  • MCV antibodies
  • Anti-mutated citrullinated vimentin
  • Anti-mutated citrullinated vimentin antibodies
  • Rheumatoid arthritis
Anti-Mutated Citrullinated Vimentin (MCV) Antibody, Serum